Header

UZH-Logo

Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 20.

Stankov, M V; Bourquin, J P; et al (2014). Histone deacetylase inhibitors induce apoptosis in myeloid leukemia by suppressing autophagy. Leukemia, 28(3):577-588.

Creutzig, U; Zimmermann, M; Bourquin, J P; Dworzak, M N; Kremens, B; Lehrnbecher, T; von Neuhoff, C; Sander, A; von Stackelberg, A; Schmid, I; Starý, J; Steinbach, D; Vormoor, J; Reinhardt, D (2012). Favorable outcome in infants with AML after intensive first- and second-line treatment: an AML-BFM study group report. Leukemia, 26(4):654-661.

Schmitz, M; Bourquin, J P; Bornhauser, B C (2011). Alternative technique for intrafemoral injection and bone marrow sampling in mouse transplant models. Leukemia and Lymphoma, 52(9):1806-1808.

Creutzig, U; Zimmermann, M; Bourquin, J P; Dworzak, M N; Fleischhack, G; von Neuhoff, C; Sander, A; Schrauder, A; von Stackelberg, A; Ritter, J; Starý, J; Reinhardt, D (2011). CNS irradiation in pediatric acute myleoid leukemia: equal results by 12 or 18 Gy in studies AML-BFM98 and 2004. Pediatric Blood & Cancer, 57(6):986-992.

Creutzig, U; Zimmermann, M; Bourquin, J P; Dworzak, M N; von Neuhoff, C; Sander, A; Schrauder, A; Teigler-Schlegel, A; Stary, J; Corbacioglu, S; Reinhardt, D (2011). Second induction with high-dose cytarabine and mitoxantrone: different impact on pediatric AML patients with t(8;21) and with inv(16). Blood, 118(20):5409-5415.

Bourquin, J P (2011). Trends in the development of novel therapies for refractory acute lymphoblastic leukemia. Schweizer Krebs-Bulletin = Bulletin Suisse du Cancer, 31(2):149-152.

Schmitz, M; Breithaupt, P; Scheidegger, N; Cario, G; Bonapace, L; Meissner, B; Mirkowska, P; Tchinda, J; Niggli, F K; Stanulla, M; Schrappe, M; Schrauder, A; Bornhauser, B C; Bourquin, J P (2011). Xenografts of highly resistant leukemia recapitulate the clonal composition of the leukemogenic compartment. Blood, 118(7):1854-1864.

Bourquin, J P; Bornhauser, B (2010). Have chemosensitizing strategies for multidrug-resistant childhood acute lymphoblastic leukemia come of age? Expert Review of Hematology, 3(4):369-372.

Bourquin, J P; Izraeli, S (2010). Where can biology of childhood ALL be attacked by new compounds? Cancer Treatment Reviews, 36(4):298-306.

Creutzig, U; Zimmermann, M; Dworzak, M; Urban, C; Henze, G; Kremens, B; Lakomek, M; Bourquin, J P; Stary, J; Reinhardt, D (2010). Favourable outcome of patients with childhood acute promyelocytic leukaemia after treatment with reduced cumulative anthracycline doses. British Journal of Haematology, 149(3):399-409.

Hertzberg, L; Vendramini, E; Ganmore, I; Cazzaniga, G; Schmitz, M; Chalker, J; Shiloh, R; Iacobucci, I; Shochat, C; Zeligson, S; Cario, G; Stanulla, M; Strehl, S; Russell, L J; Harrison, C J; Bornhauser, B; Yoda, A; Rechavi, G; Bercovich, D; Borkhardt, A; Kempski, H; te Kronnie, G; Bourquin, J P; Domany, E; Izraeli, S (2010). Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group. Blood, 115(5):1006-1017.

Bourquin, J P. Improved models for preclinical evaluation of new therapeutic agents for pediatric hematologic malignancies. 2010, University of Zurich, Faculty of Medicine.

Bonapace, L; Bornhauser, B C; Schmitz, M; Cario, G; Ziegler, Urs; Niggli, F K; Schäfer, B W; Schrappe, M; Stanulla, M; Bourquin, J P (2010). Induction of autophagy-dependent necroptosis is required for childhood acute lymphoblastic leukemia cells to overcome glucocorticoid resistance. Journal of Clinical Investigation, 120(4):1310-1323.

von Neuhoff, C; Reinhardt, D; Sander, A; Zimmermann, M; Bradtke, J; Betts, D R; Zemanova, Z; Stary, J; Bourquin, J P; Haas, O A; Dworzak, M N; Creutzig, U (2010). Prognostic impact of specific chromosomal aberrations in a large group of pediatric patients with acute myeloid leukemia treated uniformly according to trial AML-BFM 98. Journal of Clinical Oncology, 28(16):2682-2689.

Linsenmeier, C; Thoennessen, D; Negretti, L; Bourquin, J P; Streller, T; Lütolf, U M; Oertel, S (2010). Total body irradiation (TBI) in pediatric patients. A single-center experience after 30 years of low-dose rate irradiation. Strahlentherapie und Onkologie, 186(11):614-620.

Güngör, T; Scherer, F; Molinari, L; Schmugge, M; Bourquin, J P; Niggli, F; Seger, R (2009). Überlebensrate und Mortalität nach allogener und autologer hämatopoietischer Stammzelltransplantation (HSZT) an den Universitäts-Kinderkliniken Zürich: eine vergleichende Analyse von 1991 bis 2006. Schweizer Krebs-Bulletin = Bulletin Suisse du Cancer, 29(1):41-44.

Wehrli, L A; Braun, J; Buetti, L N; Hagleitner, N; Hengartner, H; Kühne, T; Lüer, S; Ozsahin, H; Beck Popovic, M; Niggli, F K; Betts, D R; Bourquin, J P (2009). Non-classical karyotypic features in relapsed childhood B-cell precursor acute lymphoblastic leukemia. Cancer Genetics and Cytogenetics, 189(1):29-36.

Dorner, M; Brandt, S; Tinguely, M; Zucol, F; Bourquin, J P; Zauner, L; Berger, C; Bernasconi, M; Speck, R F; Nadal, D (2009). Plasma cell toll-like receptor (TLR) expression differs from that of B cells, and plasma cell TLR triggering enhances immunoglobulin production. Immunology, 128(4):573-579.

Mercher, T; Raffel, G D; Moore, S A; Cornejo, M G; Baudry-Bluteau, D; Cagnard, N; Jesneck, J L; Pikman, Y; Cullen, D; Williams, I R; Akashi, K; Shigematsu, H; Bourquin, J P; Giovannini, M; Vainchenker, W; Levine, R L; Lee, B H; Bernard, O A; Gilliland, D G (2009). The OTT-MAL fusion oncogene activates RBPJ-mediated transcription and induces acute megakaryoblastic leukemia in a knockin mouse model. Journal of Clinical Investigation, 119(4):852-864.

Wiegering, V A; Kellenberger, C J; Bodmer, N; Bergstraesser, E; Niggli, F K; Grotzer, M A; Nadal, D; Bourquin, J P (2008). Conservative management of acute appendicitis in children with hematologic malignancies during chemotherapy-induced neutropenia. Journal of Pediatric Hematology/Oncology, 30(6):464-467.

This list was generated on Tue Nov 21 02:35:17 2017 CET.